NIH Regional Seminar, October 26-28 in Chicago

National Institutes of Health Regional Grants Seminar October 26-28, ChicagoNIH is hosting a Regional Seminar from October 26-28 in Chicago. Over the course of two days, approximately 60 NIH & HHS review, grants, program, and policy officials will be providing sessions on over 40 different topics in 3 different tracks: Administrators, New Investigators, and All Interests. Pre-seminar workshops are offered on topics such as human research protections, electronic research administration, intellectual property, and an administrator’s boot camp.  The seminar provides opportunities to sit down and talk to NIH and HHS experts in person, through “Meet the Expert” sessions which take place throughout the seminar.  Registration is open now. This seminar is useful if you are a research administrator or investigator new to working with NIH grants, or you have a need to understand better NIH grants policy and the breadth of NIH funding programs.  The agenda can be found here and registration information is available here.


NSF RFPs

 

The Robert Noyce Teacher Scholarship Program seeks to encourage talented science, technology, engineering, and mathematics (STEM; including computer science) majors and professionals to become K-12 STEM teachers. e program seeks to encourage institutions of higher education to develop and sustain a culture where undergraduate STEM majors, especially those of the highest achievement and ability, are encouraged and supported when they express a desire to pursue K-12 STEM teaching careers.

 


NIH Funding Opportunities and Notices for August 05, 2016

Requests for Applications

  • Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01)
    (RFA-AI-16-053)
    National Institute of Allergy and Infectious Diseases
    Application Receipt Date(s): November 10, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Understanding HIV Persistence in Infants (R01)
    (RFA-AI-16-064)
    National Institute of Allergy and Infectious Diseases
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute of Mental Health
    Application Receipt Date(s): December 7, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (R61/R33)
    (RFA-AR-17-008)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt Date(s): April 7, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33)
    (RFA-AR-17-009)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt Date(s): July 10, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer (R21)
    (RFA-CA-16-015)
    National Cancer Institute
    Application Receipt Date(s): November 4, 2016, by 5:00 PM local time of applicant organization. All applications allowed for this funding opportunity announcement are due on these dates.
  • Limited Competition for the Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Clinical Research Center (Collaborative U01)
    (RFA-DK-16-508)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): November 8, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Limited Competition for the Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Biostatistics Research Center (Collaborative U01)
    (RFA-DK-16-509)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): November 8, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Environmental Health Cohorts Maintenance and Infrastructure (R24)
    (RFA-ES-16-004)
    National Institute of Environmental Health Sciences
    Application Receipt Date(s): November 10, 2016; October 10, 2017; October 10, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Novel Methods for Obtaining Molecular Information from Archived Tissue Samples (R43/R44)
    (RFA-ES-16-012)
    National Institute of Environmental Health Sciences
    Application Receipt Date(s): December 5, 2016, by 5:00 PM local time of applicant organization

Program Announcements

  • Research on Autism Spectrum Disorders (R21)
    (PA-16-386)
    National Institute of Mental Health
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute on Deafness and Other Communication Disorders
    National Institute of Environmental Health Sciences
    National Institute of Neurological Disorders and Stroke
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these date.
  • Research on Autism Spectrum Disorders (R03)
    (PA-16-387)
    National Institute of Mental Health
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute on Deafness and Other Communication Disorders
    National Institute of Environmental Health Sciences
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Research on Autism Spectrum Disorders (R01)
    (PA-16-388)
    National Institute of Mental Health
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute on Deafness and Other Communication Disorders
    National Institute of Environmental Health Sciences
    National Institute of Neurological Disorders and Stroke
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates
  • Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02)
    (PAR-16-381)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt/Submission Date(s): October 4, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (X02)
    (PAR-16-382)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt/Submission Date(s): October 18, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Chemistry Science Track Award for Rapid Transition (C/START) (R03)
    (PAR-16-383)
    National Institute on Drug Abuse
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Chemical Discovery (CHEM) Award (R21/R33)
    (PAR-16-384)
    National Institute on Drug Abuse
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)
    (PAR-16-385)
    National Cancer Institute
    Application Receipt/Submission Date(s): November 17, 2016; June 14, 2017; November 17, 2017; June 14, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • NIMH Career Transition Award for Tenure-Track and Tenured Intramural Investigators (K22)
    (PAR-16-389)
    National Institute of Mental Health
    Application Receipt/Submission Date(s): Applications are due on the 9th of each month, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • NIBIB Trailblazer Award for New and Early Stage Investigators (R21)
    (PAR-16-390)
    National Institute of Biomedical Imaging and Bioengineering
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Surgical Disparities Research (R01)
    (PAR-16-391)
    National Institute on Minority Health and Health Disparities
    National Cancer Institute
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Office of Research on Women’s Health
    Application Receipt/Submission Date(s): November 4, 2016; June 7, 2017; June 7, 2018 and June 7, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Exploratory/Developmental Surgical Disparities Research (R21)
    (PAR-16-392)
    National Institute on Minority Health and Health Disparities
    National Cancer Institute
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Office of Research on Women’s Health
    Application Receipt/Submission Date(s): November 4, 2016; June 7, 2017; June 7, 2018 and June 7, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • NIDA Program Project Grant Applications (P01)
    (PAR-16-393)
    National Institute on Drug Abuse
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.


ORAU Opportunities due Sept. 1, 2016

ORAU Events Grant Deadline (Cycle 1):  September 1, 2017

ORAU Events Grant provide up to $4,000 in support of events which involve participants from more than one ORAU institution.  Typical events might include visits to an ORAU institution by a renowned speaker, conferences or workshops with a focused theme, or a technology transfer/business plan competition.

The deadline to submit for support for events taking place between October 1 2016 and May 31, 2017 is September 1, 2016.

Eligibility:

  • Applications must be submitted by the Councilor at any ORAU institution in good standing (i.e. membership fees and required reports for existing award programs are current).
  • Each ORAU institution may submit one request for an event during ORAU’s fiscal year (Oct. 1 – Sept. 30).
  • A representative from ORAU must be invited to the event and will attend, if possible.

For complete selection criteria, funding restrictions and instructions to apply, please see the University Partnerships Office, Events Sponsorship Program link, on the ORAU website.

***************************

 

Neutron Sciences Call for Proposals – Oak Ridge National Laboratory

Proposals for beam time at Oak Ridge National Laboratory’s High Flux Isotope Reactor (HFIR) and Spallation Neutron Source (SNS) will be accepted via the web-based proposal system.  This call is for experiments anticipated to run January through June 2017.   Proposal Deadline:  Wednesday, October 5, 2016  11:59 a.m. (EDT)

Specific information on this call and each of the instruments available during this experimental period is included on the ORNL Neutron Sciences web site. Proposals will be reviewed for feasibility, safety, and potential for high impact science.  Users for approved projects must complete access and training requirements prior to beginning experiments.

Updates:

  • Please note that ORCiD registration will be required beginning with this proposal cycle. Add your ORCID iD to your profile now to avoid delays in proposal submission.
  • Current schedule calls for reduced time available in this cycle at the Spallation Neutron Source (SNS) due to an extended maintenance outage which will begin at the end of March 2017.
  • HFIR will have four cycles scheduled during this experimental period Please see articles on these changes in our latest edition of the ORNL Neutron Times.
  • Opportunity to request Center for Nanophase Materials Sciences (CNMS) characterization time as part of your neutron proposal.

To learn more about submitting a proposal for beam time, go to http://neutrons.ornl.gov/users/proposals.shtml. 

ORAU

University Partnerships Office

University.partnerships@orau.org

www.orau.org


Defense Health Program RFP: Most due Sept. 7th

Defense Health Program
Department of Defense Peer Reviewed Orthopaedic Research Program

Funding Opportunities for Fiscal Year 2016 (FY16)

The Fiscal Year 2016 (FY16) Defense Appropriations Act provides $30 million (M) to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support innovative, high-impact orthopaedic research.  The goal of the PRORP is to provide all Warriors affected by orthopaedic injuries sustained in the defense of our Constitution the opportunity for optimal recovery and restoration of function.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website

Focus Areas:  The PRORP considers applications that specifically address the critical needs of the orthopaedic research community in one or more of the FY16 PRORP Focus Areas.  The PRORP will solicit research applications that address at least one of the following FY16 Focus Areas (Note:  Focus Area requirements vary by award mechanism):

Surgical Care Focus Areas:

  • Peripheral Nerve Injuries:  Treatment strategies to improve outcomes from segmental peripheral nerve defects of motor and mixed (motor and sensory) peripheral nerve damage from crush or complete injury.
  • Prevention of Heterotopic Ossification:  Techniques to retard or prevent the development of human post-traumatic heterotopic ossification in the upper extremity.
  • Volumetric Muscle Loss:  Techniques to regenerate functional, innervated muscle units in treatment of volumetric muscle loss.
  • Extremity Fractures:  Strategies to optimize patient outcomes after extremity fracture, i.e., time to begin rehabilitation, weight-bearing strategy.
  • Pelvic Ring Injuries:  Treatment strategies to improve outcomes of complex pelvic ring injuries.
  • Compartment Syndrome:  Strategies to improve current diagnoses for compartment syndrome.
  • Gaps in Clinical Practice Guidelines:  Address gaps in current orthopaedic clinical practice guidelines (CPG) and recommendations (http://www.usaisr.amedd.army.mil/cpgs.html).  Applications under this focus area must specify which orthopaedically relevant CPG their application is intended to support.  Applicants should also highlight the expected impact of their research on orthopaedic clinical practice.
  • Surgical Techniques to Optimize Gait:  Identify surgical techniques to optimize gait efficiency and outcomes for patients with amputation or limb salvage.
  • Soft Tissue Trauma:  Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments affecting return to duty, work, or reintegration.

Rehabilitation Focus Areas:

  • Post-Operative Pain Management:  Develop strategies for post-operative pain management following orthopaedic trauma that minimize or eliminate opioid use.  The primary outcome measures should relate to rehabilitation endpoints and not focus solely on pain scores.
  • Prosthetic and/or Orthotic Device Function:  Development and optimization of novel and/or innovative technologies to improve prosthetic and/or orthotic device function and durability, including intuitive efferent and afferent user interfaces and considerations to interoperability.
  • Secondary Physical Health Effects:  Techniques or technologies that improve prediction, identification, and reduction of secondary physical health effects (e.g., obesity, arthrosis, osteoporosis, cardiovascular disease) following severe/high-energy traumatic neuromusculoskeletal non-spinal cord injury.  The focus should be on injuries sustained between the ages of 18-50 and secondary physical health effects that develop within 5 years of injury.
  • Physical or Occupational Therapy:  Development and/or validation of optimal physical or occupational therapy treatment strategies and sequence of progression throughout the rehabilitation continuum to maximize functional outcomes following severe neuromusculoskeletal injury, excluding central nervous system.  Examples include optimal dose, timing, frequency, duration, and intensity of rehabilitation interventions.
  • Barriers to Successful Therapy Outcomes:  Identify, quantify, and stratify confounding treatable factors (e.g., pain, sleep, nutrition, compliance, etc.) that inhibit or delay optimal orthopaedic rehabilitation outcomes.
  • Rehabilitation Outcomes:  Development of validated, standardized measures to objectively assess and improve rehabilitation outcomes, including multi-extremity trauma and/or psychosocial resiliency and reintegration, following neuromusculoskeletal injury.

 

http://cdmrp.army.mil/funding/prorp.shtml

 

Applied Research Award – Preapplication due September 7, 2016

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

  • Pre-application is required; Full application submission is by invitation only.
  • Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities
  • Applications must address one and only one of the FY16 PRORP Focus Areas.
  • Proposed researchshould be supported by preliminary data and have the potential to make significant advancements toward clinical translation.

Clinical trials are not allowed under this award mechanism.

  • Maximum funding of $500,000for total costs (direct costs plus indirect costs)
  • Maximum period of performance is 3years
  • All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum years.

 

Clinical Trial Award – Preapplication due September 7, 2016

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

  • Pre-application is required; Full application submission is by invitation only.
  • Supports the rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates
  • Applications must address one and only of the FY16 PRORP Focus Areas.
  • Funding must support a clinical trial and may not be used for preclinical research studies.
  • Collaboration with military researchers and clinicians is encouraged.
  • Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.

Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.

  • Maximum funding of $3 million (M)for total costs (direct costs plus indirect costs)
  • Maximum period of performance is years.
  • All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  Applications must be submitted through the federal government’s single-entry portal, Grants.gov.   For email notification when Program Announcements are released go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org


NIH RFPS and Notices for August

Requests for Applications

  • Alzheimer’s Clinical Trials Consortium (ACTC) (U24)
    (RFA-AG-17-005)
    National Institute on Aging
    Application Receipt Date(s): February 2, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)
    (RFA-DA-17-013)
    National Institute on Drug Abuse
    Application Receipt Date(s): November 18, 2016 by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on this date.
  • Limited Competition: Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study (U01)
    (RFA-DK-16-511)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): December 7, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Clinical Centers for the NHLBI’s Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)
    (RFA-HL-17-009)
    National Heart, Lung, and Blood Institute
    Application Receipt Date(s): December 20, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
  • Data and Modeling Coordination Center for the NHLBI’s Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PrecISE) Network (U24)
    (RFA-HL-17-010)
    National Heart, Lung, and Blood Institute
    Application Receipt Date(s): December 20, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Program Announcements

  • Limited Competition: Clinical Research Investigator Supplement (CRIS) for the Maternal Fetal Medicine Units (MFMU) Network and the Neonatal Research Network (NRN) (Admin Supp)
    (PA-16-377)
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    Application Receipt/Submission Date(s): August 19, 2016 by 5:00 PM local time of applicant organization.
  • FDA Scientific Conference Grant Program (R13)
    (PAR-16-378)
    Food and Drug Administration
    Application Receipt/Submission Date(s): October 12, 2016 by 11:59 PM Eastern Time. April 12, 2017 and October 12, 2017 by 11:59 PM Eastern Time. April 12, 2018 and October 12, 2018 by 11:59 PM Eastern Time. April 12, 2019 and October 11, 2019 by 11:59 PM Eastern Time.
  • Center of Excellence for Research on Complementary and Integrative Health (P01)
    (PAR-16-379)
    National Center for Complementary and Integrative Health
    Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  • Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)
    (PAR-16-380)
    National Cancer Institute
    Application Receipt/Submission Date(s): April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018; April 11, 2019, October 11, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

NSF RFPs

 Solicitation: NSF 14-608
Due Date: August 30, 2016
Institutional Limit: 2
Limit Summary:An organization may submit no more than two Phase I proposals in total during this cycle, which is defined as this STTR Phase I solicitation and the concurrent SBIR Phase I solicitation. For example, an organization may submit one (1) SBIR Phase I and one (1) STTR Phase I proposal, two (2) SBIR Phase I proposals, or two(2) STTR Phase I proposals during this cycle.

These eligibility constraints will be strictly enforced. In the event that an organization exceeds this limit, the first two proposals received will be accepted, and the remainder will be returned without review). No exceptions will be made.

The submission of the same project idea to both this STTR Phase I solicitation and the concurrent SBIR Phase I solicitation is strongly discouraged.

 

 Solicitation: NSF 14-603
Due Date: August 30, 2016
Institutional Limit: 2
Limit Summary:An organization may submit no more than two Phase I proposals in total during this cycle, which is defined as this SBIR Phase I solicitation and the concurrent STTR Phase I solicitation. For example, an organization may submit one (1) SBIR Phase I and one (1) STTR Phase I proposal, two (2) SBIR Phase I proposals, or two(2) STTR Phase I proposals during this cycle.

These eligibility constraints will be strictly enforced. In the event that an organization exceeds this limit, the first two proposals received will be accepted, and the remainder will be returned without review. No exceptions will be made.

The submission of the same project idea to both this SBIR Phase I solicitation and the concurrent STTR Phase I solicitation is strongly discouraged.

 


RFP for Mn DOT due Sept. 12

I am pleased to announce our Research Request for Proposals (RFP) for FY 2018 MnDOT and LRRB Research funding cycle. Please visit the MnDOT Research Services web site for all the details and the deadlines for submitting your proposals.  Here is the link to the website:

http://www.dot.state.mn.us/research/RFP/FY2018/index.html

Please note that the deadline for proposals to you, the university contacts, is Monday, September 12, 2016 and then the deadline for proposals to me is Wednesday, September 14, 2016.

We have updated our “Project Proposal Form” with special requirements for documenting key potential benefits and implementation opportunities.  All the questions in the “Project  Proposal Form” must be answered. Incomplete proposals will not be considered for further evaluation.

Feel free to contact me with your questions and comments.

Hafiz

Hafiz Munir, Ph.D., P.E.

Supervisor, Research Management Unit

MnDOT Research Services

395 John Ireland Boulevard

St. Paul, MN 55155-1899

Phone:  651-366-3757

Fax:  651-366-3789

Email:  Hafiz.Munir@state.mn.us


Fair Labor Standards Act (FLSA) final over time rule: NSF award FAQs

Dear Colleagues:

The Department of Labor recently announced the Fair Labor Standards Act (FLSA) final over time rule. The FLSA final overtime rule automatically extends overtime pay protections to millions of workers and could impact some personnel on NSF grants, including postdoctoral researchers. The National Science Foundation continues to acknowledge the important role of postdoctoral researchers on NSF-funded projects, and, in general, NSF postdoctoral programs already include a stipend or salary in excess of the new minimum established by the FLSA final overtime rule.

Since the announcement of the new rule, NSF has received many questions on how this rule will affect NSF-funded projects. NSF has created a set of Frequently Asked Questions in order to address these questions. The FAQs are posted on the NSF Policy Office website at http://www.nsf.gov/bfa/dias/policy/faqs/flsa_faqs.pdf.

We encourage you to share this information with your colleagues. Please direct any additional policy-related questions not addressed in the FAQs topolicy@nsf.gov.

Regards,

Jean

Jean Feldman

Head, Policy Office

Division of Institution & Award Support (DIAS)

Office of Budget, Finance and Award Management